Amr Hassan, profile picture
Uploaded byAmr Hassan
PDF, PPTX3,085 views

Progressive multifocal leukoencephalopathy (PML)

This document discusses progressive multifocal leukoencephalopathy (PML), an opportunistic infection caused by the John Cunningham virus (JCV) that leads to demyelination in the central nervous system. It highlights the epidemiology, clinical manifestations, diagnostic methods, and risk factors associated with PML, particularly in immunocompromised patients and those undergoing immunomodulatory therapies. It also presents data on the incidence of PML in patients treated with natalizumab and other therapies, addressing the relationships between these treatments and the development of PML.

Embed presentation

Download as PDF, PPTX
Amr Hassan, MD,FEBN Professor of Neurology Cairo University - Egypt Progressive multifocal leukoencephalopathy (PML)
▪ John Cunningham virus (JCV) is a double-stranded DNA polyomavirus. ▪ Takes its name from the initials of the patient from whom it was first isolated. ▪ PML was initially described in patients with underlying B-cell lymphoproliferative disorders [1] JC virus
JC virus
Progressive Multifocal Leukoencephalopathy
JCPyV and the development of PML
JCPyV and the development of PML
JCPyV and the development of PML
▪ 50-90% of adults have been exposed to this virus ▪ 19-27% of these people shedding JCV in their urine.[5,7-10] ▪ Acquisition of this virus is not associated with a clinical syndrome.[9] ▪ Opportunistic infection, caused by the polyoma virus JC virus ▪ Characterized by focal demyelination in the CNS ▪ Worldwide distribution, seroprevalence of 39-69% in adults ▪ Primary infection usually in childhood ▪ No recognized acute JC virus infection ▪ Likely asymptomatic chronic carrier state PML: epidemiology
In a large review spanning the 30 years from 1958 to 1984, only 230 cases were identified, with only 69 being confirmed pathologically. PML: epidemiology
PML: epidemiology
• B-cell malignancies • Other myeloproliferative diseases, • Carcinomas • Congenital immune deficiencies • Organ transplantation • Granulomatous, inflammatory,or other immune- mediated conditions. • 3-7% of persons with AIDS Conditions associated with PML
– Adenosine deaminase deficiency – CD40 ligand deficiency – Comimmune deficiency bined – Common variable immune deficiency – DOCK8 (dedicator of cytokinesis 8 protein) deficiency – Gamma heavy chain disease – Hyper-IgM syndrome – Immunodeficiency-centromeric instability-facial dysmorphism syndrome syndrome –Purine nucleoside phosphorylase deficiency – Severe combined immune deficiency – Signal transducer and activator of transcription 1 gain-of-function immune deficiency – Wiskott-Aldrich syndrome – X-linked agammaglobulinaemia – Idiopathic CD4+ lymphopenia* Zerbe CS, Marciano BE, Katial RK, Santos CB, Adamo N, Hsu AP, et al.Progressive Multifocal Leukoencephalopathy in Primary Immune Deficiencies: Stat1 Gain of Function and Review of the Literature. Clin Infect Dis. 2016;62(8):986–94. Hereditary immune deficiencies linked to PML
– Human immunodefiency infection or acquired immune deficiency syndrome – Haematopietic stem cell transplantation – Immunosuppressive therapy in organ transplant recipients – Haematological malignancies (e.g. lymphomas and leukaemias) – Immunosuppression during chemotherapy of solid cancers – Systemic lupus erythematosus – Sarcoidosis – Immunosuppressive or -modulatory therapy in autoimmune diseases (rheumatoid arthritis, psoriatic arthritis, psoriasis, juvenile idiopathic arthritis, inflammatory bowel disease, ankylosing spondylitis, multiple sclerosis) Brew BJ, Davies NW, Cinque P, Clifford DB, Nath A. Progressive multifocal leukoencephalopathy and other forms of JC virus disease. Nat Rev Neurol. 2010;6(12):667–79. Amend KL, Turnbull B, Foskett N, Napalkov P, Kurth T, Seeger J. Incidence of progressive multifocal leukoencephalopathy in patients without HIV. Neurology. 2010;75(15):1326–32. doi Acquired immune deficiencies linked to PML
Organ Transplant: Heart, lung, kidney 1/1000 HIV AIDS-defining 1/100 without HART 6/10.000 with HAART Bone marrow Transplant 3.5/10.000 per year Hematologic Malignancies 8.3/100.000 per year In lymphoma Immunomodulatory Treatments (e.g.in MS) Rheumatologic Conditions 1/100.000 per year Conditions associated with PML
– Natalizumab – Efalizumab – Belimumab – Rituximab – Fingolimod – Dimethylfumarate – Alemtuzumab – Tumour necrosis factor-alpha inhibitors (infliximab, adalimumab, etanercept) – Ofatumumab – Mycophenolate mofetil – Betalacept – Brentuximab – Fludarabine – Ruxolitinib – Leflunomide Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med. 2010;61(1):35–47. Brew BJ, Davies NW, Cinque P, Clifford DB, Nath A. Progressive multifocal leukoencephalopathy and other forms of JC virus disease. Nat Rev Neurol. 2010;6(12):667–79. Zaheer F, Berger JR. Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps. Ther Adv Drug Saf. 2012;3(5):227–39. Berger JR. Classifying PML risk with disease modifying therapies. Mult Scler Relat Disord. 2017;12:59–63. Immunomodulatory treatments linked to PML
– Natalizumab – Efalizumab – Belimumab – Rituximab – Fingolimod – Dimethylfumarate – Alemtuzumab – Tumour necrosis factor-alpha inhibitors (infliximab, adalimumab, etanercept) – Ofatumumab – Mycophenolate mofetil – Betalacept – Brentuximab – Fludarabine – Ruxolitinib – Leflunomide Immunomodulatory treatments linked to PML Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med. 2010;61(1):35–47. Brew BJ, Davies NW, Cinque P, Clifford DB, Nath A. Progressive multifocal leukoencephalopathy and other forms of JC virus disease. Nat Rev Neurol. 2010;6(12):667–79. Zaheer F, Berger JR. Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps. Ther Adv Drug Saf. 2012;3(5):227–39. Berger JR. Classifying PML risk with disease modifying therapies. Mult Scler Relat Disord. 2017;12:59–63.
Least concern : Interferon beta, glatiramer acetate Some concern: Alemtuzumab (Lemtrada) Teriflunamide (Aubagio) Fingolimod (Gilenya) Dimethyl fumarate (Tecfidera) High concern: Natalizumab (Tysabri) Carson et al. 2009; Berger et al. 2013 Concern for PML
26 • Focal neurologic deficits, usually with insidious onset, steady progression over several weeks/months • Demyelinating lesions may involve any region of the brain – Common: occipital lobes (hemianopsia), frontal and parietal lobes (aphasia, hemiparesis, hemisensory deficits), cerebellar peduncles and deep white matter (dysmetria, ataxia) – Spinal cord involvement is rare PML: Clinical Manifestations
27 • Headache and fever not characteristic (except in severe IRIS) • Seizures in 20% • Cognitive dysfunction may occur but diffuse encephalopathy or dementia is rare PML: Clinical Manifestations
PML: Radiological diagnosis An early progressive multifocal leukoencephalopathy (PML) patient within 6 days of PML diagnosis with a large (A) T2-hyperintense and (B) fluid- attenuated inversion recovery–hyperintense lesion in the right frontal lobe. The lesion was (C) T1 hypointense and (D) diffusion-weighted imaging hyperintense, with sharp scalloped borders toward the gray matter and illdefined borders toward the white matter.
PML: Radiological diagnosis
30 PML, CT scan PML, MRI scan PML: Radiological diagnosis CT scan: single or multiple hypodense, nonenhancing white matter lesions
PML: Radiological diagnosis Progressive multifocal leukoencephalopathy (PML) radiographically. (a) Typical lesion of PML as a T2 hyperintensity involving large portion of 1 hemisphere. (b) T2 fluid-attenuated inversion recovery image demonstrating hyperintensity in the bilateral cerebellum consistent with PML
PML: Radiological diagnosis Contrast enhancement in 10-15% but usually sparse, IRIS PMN may have different appearance An early progressive multifocal leukoencephalopathy (PML) patient who developed PML-immune reconstitution inflammatory syndrome (IRIS). At the time of PML diagnosis, this patient had (A) a diffuse T2-hyperintense lesion in the right frontal lobe and (B, arrows) multiple punctate T2 lesions in the vicinity of the main lesion. The lesion was (C) T1 hypointense and (D) DWI hyperintense. (E) The lesion had increased in size by the IRIS phase, which was 37 days after the first scan, and (F) exhibited contrast enhancement on T1-weighted (T1W) imaging. (G) Ten days later, there was a T1-hyperintense rim around the lesion on precontrast T1W imaging, which (H) did not enhance postcontrast, although punctate enhancement was seen in the contralateral hemisphere.
PML: Radiological diagnosis Diffusion-weighted imaging and MR spectroscopy may give additional diagnositic information FIGURE 3: (A) In this early progressive multifocal leukoencephalopathy (PML) patient, PML was difficult to distinguish from the confluent lesion burden on the fluid-attenuated inversion recovery (FLAIR) image. (B) However, the hyperintensity in diffusion- weighted imaging identified new areas of abnormality. A further magnetic resonance examination 6 days later showed (C) an increase in size of the right frontal lesion on FLAIR with (D) T1 hypointensity.
PML: Radiological diagnosis FIGURE 4: A patient with an early progressive multifocal leukoencephalopathy lesion filling a segment of the precentral gyrus. The lesion was (A) T2 hyperintense, (B) hyperintense on diffusion- weighted imaging, and (C–E) more readily seen on fluid-attenuated inversion recovery (FLAIR). (A, C) Punctate T2-/FLAIR-hyperintense lesions were seen in the vicinity of the main lesion. (D) The lesion increased in size during the IRIS phase (D; 51 days after the first scan) and (E) the post- IRIS phase (85 days after the first scan). No enhancement was noted at any stage.
PML: Radiological diagnosis FIGURE 5: An early progressive multifocal leukoencephalopathy (PML) patient, 9 days prior to PML diagnosis, shows (A) an unusual cluster of punctate T2- hyperintense lesions, many of which (B) were enhanced with contrast on T1-weighted (T1W) imaging and were diffusion- weighted imaging (DWI) hyperintense. (D) The lesions became confluent on a T2- weighted followup scan 30 days later. (E) There was no contrast enhancement on T1W imaging, but (F) the cluster remained hyperintense on DWI.
From: Natalizumab-Associated Progressive Multifocal Leukoencephalopathy in a Patient With Multiple Sclerosis: A Postmortem Study J Neuropathol Exp Neurol. 2013;72(11):1043-1051. doi:10.1097/NEN.0000000000000005 J Neuropathol Exp Neurol | © 2013, by the American Association of Neuropathologists, Inc. PML: Radiological diagnosis
PML: Radiological diagnosis Magnetic resonance imaging evaluation of multiple sclerosis (MS) and progressive multifocal leukoencephalopathy (PML). After receiving 55 infusions of Natalizumab (May 2013). Axial FLAIR (A) and corresponding contrast enhanced T1W images (B) show MS lesions in the periventricular white matter and a new area of hyperintense FLAIR signal (white arrow) and faint enhancement (black arrow) in the left parietal subcortical white matter.
PML: Radiological diagnosis
PML: Radiological diagnosis Figure 3: Evolution of progressive multifocal leukoencephalopathy – Immune reconstitution inflammatory syndrome (PML-IRIS). Axial FLAIR and corresponding contrast enhanced T1W images through the parietal lobe. (A) Ten weeks after Natalizumab discontinuation and before steroid treatment (October 21, 2013), there is further extension of the parietal lobe white matter lesion (white arrows) with associated enhancement (black arrowheads). (B) Eleven weeks after Natalizumab discontinuation and after IV steroid therapy (October 29, 2013), there is decreased enhancement without change in FLAIR signal abnormality. (C) 6- month follow up after steroid treatment, there is further improvement with complete
Elizabeth C. Neil, and Lisa M. DeAngelis Blood Adv 2017;1:2041-2045 © 2017 by The American Society of Hematology PML: Radiological diagnosis
Features Characteristics Location Subcortical Location is the prime site,thereby involving U-fibers cortex and basal ganglia are often involved; often bilatcral Size Usually > 3cm Borders Sharp toward the gray matter, ill defined toward the white matter Mode of extension Lesions increase in size and new lesions appear Mass effect No mass effect in small or large lesions T2W images Always hyperintense T1W images Typically hypointense ; no reversion of signal intenstiy; hyperintensity is suggestive of PML- IRIS FLALR Always hyperintense ; better appreciated than om T2W images DW images Always hyperintense ; in larger lesions there is a hyperintense rim at the lesion’s edge Perilesional Small, punctate T2-hyperintense lesions in the immediate vicinity of the main lesion are often present Enhancement Frequent enhancement, punctate and/or rimlike Atrophy No atrophy in the early phase Ann Neurol.2012 Nov;72(5):779-87. doi: 10.1002/ana.23676. PML: Radiological diagnosis
• CSF evaluation for JC virus DNA (BY PCR): helpful positive; 70-90% sensitive in patients who are not on ART(lower in those on ART) • Specificity 92-100% • Sensitivity 72-93% • Serologic testing generally not useful,but newer approaches under investigation PML: diagnosis
PML: Brain biopsy • Identification of JC virus; • Oligodendrocytes with intranuclear inclusions • Bizarre astrocytes, • Lipid-laden macrophages
Berger et al. 2013
Features indicative of MS PML Onset Acute Sub-acute Evolution • Over hours to days • Normally stabilise • Resolve spontaneously even without therapy • Over weeks • progressive Clinical Presentation • Diplopia • Paraesthesia • Paraparesis • Optic neuritis • myelopathy • Aphasia • Behavioural or cognitive changes and neuropsychological alteration • Retrochiasmal visual deficits • Hemiparesis • Seizures • Ataxia (for GCN) PML Vs An attack
Fernández et al Neurologia 2012;27:432-41 PML Vs An attack
Pei-Ran Ho et al., Risk of natalizumab-associated progressive multifocal eukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies.Lancet,2017.S1474-4422(17)30335-6 PML and Natalizumab
Global Natalizumab PML Risk Estimates by Treatment Epoch :March 2017
As of November 30, 2017, the global overall incidence of PML in natalizumab-treated patients is: 4.19 per 1000 patients (95% CI 3.89 to 4.49 per 1000 patients). As of December 7, 2017 there have been 756 confirmed PML cases (753 MS, 3 CD), (205 US, 480 EEA, 71 ROW) 76.5% of patients were alive with varying levels of disability* As of December 7, 2017, the duration of natalizumab dosing prior to PML diagnosis ranged from 8 to 136 doses Biogen, data on file.2017 PML and Natalizumab
PML and MS therapeutics
PML and Fingolimod
PML Cases in Patients Switching From Natalizumab to Fingolimod • Cases reported at ECTRIMS 2014 • Background: Now >135,800 patient-years of experience with fingolimod accumulated; about 15–20% of patients were pre-exposed to natalizumab1 • Objective: To investigate characteristics of the PML cases under fingolimod (post natalizumab)1 • Data from Novartis pharmacovigilance database1 • 11 reports of PML to date; most had fairly long exposure to natalizumab (2.5–6.0 years, mean 4 years, median 5 years)1,2 • 10/11 cases had PML before fingolimod start or PML occurred within 6 months after switch to fingolimod (washout (n=4) 1–5 months, information around JCV status not always known) • 1 additional case; no previous exposure to natalizumab was reported as PML after 7 months of fingolimod treatment; clinical features and MRI evolution consistent with neuromyelitis optica. Diagnosis made based on the results of CSF showing low copy number of JCV1 • The presenter argued for vigilance for PML following natalizumab discontinuation1 1. Putzki N et al. ECTRIMS 2014. FC3.1; 2. Medscape Pharmacists. September 25, 2014. 52
PML and Fingolimod
PML and Fingolimod
PML cases with Gilenya in patient not pre-treated with Tysabri • 1st case reported in Feb 2015 1,2 • 49 year old male diagnosed with RRMS in 2009. Received prior treatment with Rebif which was discontinued without initiating any other treatment, switched to Gilenya in October 2010. Diagnosed with PML in January 2015 • No co-existing conditions reported, no concurrent treatment along with Gilenya, never received Tysabi • 2nd case reported in July 20153,4 • 54 year old female, developed PML after taking fingolimod for ~ 2.5 years. The patient had a 13-14 year history of MS and was previously treated with Betaferon for ~ 11 years. She also received mesalazine for ulcerative colitis for the last 4 years • FDA issued a warning regarding the 2 PML cases on Gilenya3 • 3rd case reported on August 17, 20154 • Patient had a history of colorectal cancer treated with chemotherapy and radiation treatment, as well as Crohn’s disease. The role of various risk factors are currently evaluated 55 1. Novartis Press Release on Feb 16, 2015, available on http://www.novartis.com/newsroom/product-related-info-center/gilenya-safety-update.shtml 2. https://beta.mssociety.ca/research-news/article/case-of-pml-reported-in-patient-treated-with-gilenya (accessed Aug 24, 2015). 3. www.fda.gov/Drugs/DrugSafety/ucm456919.htm (accessed Aug 24, 2015) 4. www.medscape.com/viewarticle/849015.
PML and DMF
5 cases were associated with DMF use for multiple sclerosis 14 cases for psoriasis. PML and DMF
PML cases with dimethyl fumarate 1. Rosenkranz et al New Engl. J Med 2015; 372: 1476-1478. 2.http://www.bfarm.de/SharedDocs/Risikoinformationen/Pharmakovigilanz/DE/RI/2015/RI-dimethylfumarat.html Accessed July 21, 2015. 3. http://www.medpagetoday.com/Neurology/MultipleSclerosis/52622?isalert=1&uun=g274661d4296R5269425u&xid=NL_breakingnews_2015-07-16, accessed July 21, 2015 4. Nieuwkamp, e al New Engl. J Med 2015; 372: 1474-1476, 5. Philipp et al 2013 et al, Eur. J Dermatol 2013; 23(3): 339-43 6. Spencer et al, Neurol Neuroimmunol Neuroinflamm 2015;2:e76 • Case 11 : Female, 4.5 years on DMF (participated in the DEFINE trial) • 3.5 years having severe lymphopenia (start 12 month after tx initiation, lymphocyte count, 290 to 580 cells per mm3). Died from complications of pneumonia. • On April 7, 2015, the German authorities mentioned 2 PML cases with Tecfidera (+ 9 with Fumaderm) but no details provided2 • On July 17, 2015, also Biogen confirmed a 2nd PML case with Tecfidera, (likewise no details provided)3 • Role of lymphopenia • About 2% of patients treated with DMF develop lymphopenia < 500 cells per mm3)1 • Monitoring of lymphocyte recommended to prevent severe opportunistic infections4* • In April 2015, Nieuwkamp et al published a PML case with (compounded) DMF for the tx of psoriasis. This patients had no major lymphopenia (nadir 792 cells per mm3) and no other immunosuppressive therapies4 *Researchers increasingly recommend to determine besides the commonly-used differential blood counts also lymphocyte subsets (mainly CD4+ and CD8+ Tcells)5,6Depletion of CD8+ T cells seems to be more pronounced than that of CD4+T cells.6 58
The PML case with dimethyl fumarate led to label change in the US 59 Description of the fatal PML case with Tecfidera and initial signs/symptoms of PML Recommendation to obtain complete blood count (CBC) at baseline, after month 6 and in due course every 6-12 months. Interrupt treatment if lymphocyte counts are < 0.5 x 109/L persisting for more than 6 months Note: According to the European label, CBC should be obtained at baseline, after 6 months and thereafter every 6-12 months. No mention of PML in the label Tecfidera US prescribing information, European Tecfidera prescribing information
PML and Teriflunomide
• A single fatal case • Reported in a patient who switched from natalizumab to alemtuzumab. • however, retrospective analysis of the MRI data showed that the onset of PML predated alemtuzumab treatment and, therefore, was attributed to natalizumab treatment Thomas Berger et al., Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts.CNS Drugs. 2017; 31(1): 33–50. PML and Alemtuzumab
PML and Ocrelizumab
• No specific treatment • Restoring the immune system: • Antiretrovirals in HIV • Plasma exchange to remove natalizumab • No proven benefit: Ara C, IFN gamma, IL-2, cidofovir, mefloquine, mirtazapine • Case report: 2 patients with CD4 lymphopenia IL-7 and vaccination with JCV VP1 protein Sospedra et al. 2014 Treatment of PML
• Plasma exchange x3 (over 5-8 days) • Accelerates clearance of free natalizumab • (but still alpha-4 integrin receptor binding) • Side effects: clearance of other medications, hypotension, pulmonary edema (volume shift) Khatri et al. 2009 Treatment of PML
▪ Younger age at PML diagnosis ▪ Lower pre-PML EDSS ▪ Lower JC viral load at diagnosis ▪ More localised brain involvement by MRI at the time of diagnosis ▪ Asymptomatic at diagnosis Factors that appear to be associated with improved survival Factors that do not appear to affect survival ▪ Gender ▪ Prior immunosuppressant therapy ▪ MS duration ▪ Natalizumab exposure at PML diagnosis ▪ Gd enhancement on MRI at diagnosis Survival in PML
• Clinical worsening due to improvement of immune function rapid worsening. • Neurological symptoms, fever, seizure. • In most patients with natalizumab (up to 90%). • 3-6 weeks after antiretrovirals or plasma exchange. Immune Reconstitution Syndrome (IRIS)
Enlarged lesions Contrast enhancement Mass effect Immune Reconstitution Syndrome (IRIS)
Copyright © 2007 American Medical Association. All rights reserved. From: Potential Risk of Progressive Multifocal Leukoencephalopathy With Natalizumab TherapyPossible Interventions Arch Neurol. 2007;64(2):169-176. doi:10.1001/archneur.64.2.169
THANK YOU amrhasanneuro@kasralainy.edu.eg

More Related Content

PPTX
Demyelinating diseases of CNS
byAnkita Sain
 
PPTX
Sub acute sclerosing panencephalitis
byNeurologyKota
 
PPTX
Progressive multifocal leukoencephalopathy
byNeurology Residency
 
PPTX
Rituximab In Neurologic Disorders
byPIYUSH SAVALIYA
 
PPTX
Multiple sclerosis
bymuneshwarsah1
 
PDF
Novel biomarkers in Multiple sclerosis
byAmr Hassan
 
PPTX
neurodegeneration due to braiin iron accumulation
bySachin Adukia
 
PDF
Pediatric multiple sclerosis
byAmr Hassan
 
Demyelinating diseases of CNS
byAnkita Sain
 
Sub acute sclerosing panencephalitis
byNeurologyKota
 
Progressive multifocal leukoencephalopathy
byNeurology Residency
 
Rituximab In Neurologic Disorders
byPIYUSH SAVALIYA
 
Multiple sclerosis
bymuneshwarsah1
 
Novel biomarkers in Multiple sclerosis
byAmr Hassan
 
neurodegeneration due to braiin iron accumulation
bySachin Adukia
 
Pediatric multiple sclerosis
byAmr Hassan
 

What's hot

PPTX
Macrophage activation syndrome
byRishit Harbada
 
PPTX
Progressive Multifocal Leucoencephalopathy
byRoopchand Ps
 
PPTX
Viral encephalitis
byPrateek Singh
 
PPTX
Autoimmune encephalitis
byNeurologyKota
 
PPTX
CNS infections in HIV
byMadhu Reddy
 
PPTX
Fungal infection of cns
byDr Praveen kumar tripathi
 
PPTX
CEREBRAL VENOUS THROMBOSIS
byNija Panchal
 
PPTX
Neurological manifestations of HIV
byGarima Aggarwal
 
PPT
False localising signs : a major examination finding
byChetan Ganteppanavar
 
PPT
Hsv encephalitis final
bywafaa al shehhi
 
PPTX
Tb meningitis
byajayyadav753
 
PPTX
Tuberculosis of the Central Nervous system
byPramod Krishnan
 
PPTX
Approach to a patient of spastic paraplegia
byDeepanshu Khanna
 
PPTX
Neurologic manifestation of HIV/AIDS
byPS Deb
 
DOC
Neurocutaneous markers
byKurian Joseph
 
PPTX
Chronic meningitis
byDhananjay Gupta
 
PPTX
Neuromyelitis Optica
bysm171181
 
PPTX
Fungal infections of CNS
byNeurologyKota
 
PPTX
Epilepsy Syndromes
bydahmed hamed
 
PPTX
Practical approach to fever with altered liver functions
byikramdr01
 
Macrophage activation syndrome
byRishit Harbada
 
Progressive Multifocal Leucoencephalopathy
byRoopchand Ps
 
Viral encephalitis
byPrateek Singh
 
Autoimmune encephalitis
byNeurologyKota
 
CNS infections in HIV
byMadhu Reddy
 
Fungal infection of cns
byDr Praveen kumar tripathi
 
CEREBRAL VENOUS THROMBOSIS
byNija Panchal
 
Neurological manifestations of HIV
byGarima Aggarwal
 
False localising signs : a major examination finding
byChetan Ganteppanavar
 
Hsv encephalitis final
bywafaa al shehhi
 
Tb meningitis
byajayyadav753
 
Tuberculosis of the Central Nervous system
byPramod Krishnan
 
Approach to a patient of spastic paraplegia
byDeepanshu Khanna
 
Neurologic manifestation of HIV/AIDS
byPS Deb
 
Neurocutaneous markers
byKurian Joseph
 
Chronic meningitis
byDhananjay Gupta
 
Neuromyelitis Optica
bysm171181
 
Fungal infections of CNS
byNeurologyKota
 
Epilepsy Syndromes
bydahmed hamed
 
Practical approach to fever with altered liver functions
byikramdr01
 

Similar to Progressive multifocal leukoencephalopathy (PML)

PPTX
Progressive Multifocal Leukoencephalopathy
byAde Wijaya
 
PPTX
Natalizumab
byMohamadAlhes
 
PPTX
POLYOMAVIRIDEA JC VIRUS - Structure and disease( pathogenesis, replication, ...
by511RithikaR
 
PDF
Immune Reconstitution Inflammatory Syndrome (IRIS) Associated Multifocal Leuk...
byInternational Multispeciality Journal of Health
 
PPTX
NEUROIMAGING IN HIV AND NEUROINFECTIONS.pptx
byArya Anish
 
PDF
Progressive multifocal leukoencephalopathy
byProfessor Yasser Metwally
 
PPTX
PML - patient case study - Sharon Letissier
byMS Trust
 
PDF
Analysis of lesion development pml
byClaudia Pfleger
 
PPTX
Pathology of JC Virus
byYonah Ziemba
 
PPTX
Brain Imaging in Patients with HIV Infection
byAde Wijaya
 
PDF
'Approach to cns demyelinating disorders
byDrVikas Balania
 
PPTX
Radiology of demyelinating diseases
byNeurologyKota
 
PPT
2008 guidelines for_prevention_and_treatment_of_opportunistic_4
byChandan N
 
PPTX
Multiple sclerosis and newer concept in management till 2014 may
bydrnikhilver
 
PPT
A Case of CNS Toxoplasmosis
byStanley Medical College, Department of Medicine
 
PPTX
Worries bij de behandeling van MS - Dr. K. Geens
byEric Tack
 
PPTX
Multiple Sclerosis
bySrirama Anjaneyulu
 
PPTX
Multiple sclerosis
byCataldo Pinzino
 
PPT
Multiple sclerosis
byRawalpindi Medical College
 
PPTX
Imaging of cns viral infection
bysks200166
 
Progressive Multifocal Leukoencephalopathy
byAde Wijaya
 
Natalizumab
byMohamadAlhes
 
POLYOMAVIRIDEA JC VIRUS - Structure and disease( pathogenesis, replication, ...
by511RithikaR
 
Immune Reconstitution Inflammatory Syndrome (IRIS) Associated Multifocal Leuk...
byInternational Multispeciality Journal of Health
 
NEUROIMAGING IN HIV AND NEUROINFECTIONS.pptx
byArya Anish
 
Progressive multifocal leukoencephalopathy
byProfessor Yasser Metwally
 
PML - patient case study - Sharon Letissier
byMS Trust
 
Analysis of lesion development pml
byClaudia Pfleger
 
Pathology of JC Virus
byYonah Ziemba
 
Brain Imaging in Patients with HIV Infection
byAde Wijaya
 
'Approach to cns demyelinating disorders
byDrVikas Balania
 
Radiology of demyelinating diseases
byNeurologyKota
 
2008 guidelines for_prevention_and_treatment_of_opportunistic_4
byChandan N
 
Multiple sclerosis and newer concept in management till 2014 may
bydrnikhilver
 
A Case of CNS Toxoplasmosis
byStanley Medical College, Department of Medicine
 
Worries bij de behandeling van MS - Dr. K. Geens
byEric Tack
 
Multiple Sclerosis
bySrirama Anjaneyulu
 
Multiple sclerosis
byCataldo Pinzino
 
Multiple sclerosis
byRawalpindi Medical College
 
Imaging of cns viral infection
bysks200166
 

More from Amr Hassan

PDF
Parkinson disease.pdf
byAmr Hassan
 
PDF
Sequencing in management of Multiple sclerosis
byAmr Hassan
 
PDF
Myathenia Gravis
byAmr Hassan
 
PDF
Prediction of outcome of Multiple sclerosis
byAmr Hassan
 
PDF
Lifestyle modification in epilepsy
byAmr Hassan
 
PDF
Childhood demyelinating syndromes
byAmr Hassan
 
PDF
Diabetic polyneuropathy
byAmr Hassan
 
PDF
Excessive daytime sleepiness
byAmr Hassan
 
PDF
Vagal Nerve stimulation
byAmr Hassan
 
PDF
Dystonia
byAmr Hassan
 
PDF
Trigeminal neuralgia
byAmr Hassan
 
PDF
Brain stimulants
byAmr Hassan
 
PDF
Nystagmus
byAmr Hassan
 
PDF
Basics of Neuroradiology
byAmr Hassan
 
PDF
Cerebral venous sinus thrombosis
byAmr Hassan
 
PDF
Childhood and juvenile movement disorders
byAmr Hassan
 
PDF
New Antiepileptic drugs
byAmr Hassan
 
PDF
Zonisamide
byAmr Hassan
 
PDF
stem cell transplantation in pediatric neurology
byAmr Hassan
 
PDF
Tics and dyskinesias
byAmr Hassan
 
Parkinson disease.pdf
byAmr Hassan
 
Sequencing in management of Multiple sclerosis
byAmr Hassan
 
Myathenia Gravis
byAmr Hassan
 
Prediction of outcome of Multiple sclerosis
byAmr Hassan
 
Lifestyle modification in epilepsy
byAmr Hassan
 
Childhood demyelinating syndromes
byAmr Hassan
 
Diabetic polyneuropathy
byAmr Hassan
 
Excessive daytime sleepiness
byAmr Hassan
 
Vagal Nerve stimulation
byAmr Hassan
 
Dystonia
byAmr Hassan
 
Trigeminal neuralgia
byAmr Hassan
 
Brain stimulants
byAmr Hassan
 
Nystagmus
byAmr Hassan
 
Basics of Neuroradiology
byAmr Hassan
 
Cerebral venous sinus thrombosis
byAmr Hassan
 
Childhood and juvenile movement disorders
byAmr Hassan
 
New Antiepileptic drugs
byAmr Hassan
 
Zonisamide
byAmr Hassan
 
stem cell transplantation in pediatric neurology
byAmr Hassan
 
Tics and dyskinesias
byAmr Hassan
 

Recently uploaded

PDF
PEDIATRIC CATARACT & IT'S MANAGEMENT BY SAMIKSHA RAI
bySamikshaRai22
 
PPT
Frameworks for Identifying Systemic Sclerosis and Its Complications: From Pat...
byPVI, PeerView Institute for Medical Education
 
PPT
Pathways to Personalized Remission in CLL: Leveraging Targeted Standards & Ne...
byPVI, PeerView Institute for Medical Education
 
PDF
How Nepali Politics Collapsed the Health System l A Critical Analysis
byPublic Health Concern Nepal
 
PDF
Tyler Hughey Gainesville FL - A Dual-Certified Cardiovascular Sonographer
byTyler Hughey Gainesville FL
 
PDF
KNEE JOINT -Prof.Dr.N.Mugunthan, KMMC Medical College & Hospitals.pdf
byKanyakumari Medical Mission Research Center, Muttom
 
PDF
Regulatory Guidelines for Biosimilars.pdf
byManoj Konde
 
PDF
Cognitive Shadows : Analyzing Modern Traversals of Trauma-Based Mind Control ...
byGAURAV. H .TANDON
 
PPTX
Systemic Sclerosis (Scleroderma): Clinical Features, Investigations, and Mana...
byAkif Ibn Salam
 
PPTX
Histology of Musculoskeletal Tissues.pptx
byDaniel Komolafe
 
PPTX
How to Transform Clinical Practice into Evidence: A Practical Guide to Eviden...
byDaradia: The Pain Clinic
 
PDF
Best Ayurvedic Sexologist in Madhepura, Bihar Dr. Sunil Dubey
byDubey Clinic
 
PPTX
JANUARY 2026 ONCOLOGY CARTOONS BY DR KANHU CHARAN PATRO
byKanhu Charan
 
PPTX
Special Senses (RIT): Vision, Hearing & Taste Explained with Clinical Correlates
byBALAJI SOMA
 
PPTX
Fetal Skull detailed study in Obstetrics mainly for medicos
byJoslinPratheejaJ
 
PPTX
Sweet Dreams - an ILC Partners webinar on sleep
byILC- UK
 
PDF
How to Obtain Your Medical Certificate Digitally
bydoccertau
 
PDF
Best Selection of Sexologist in Munger, Bihar Male Sexual Problems Dr. Sunil ...
byDubey Clinic
 
PPTX
Immunologic disorders.pptx pathology for pharmacy
bytadessefiraol9
 
PPTX
Human Excretory System (RIT): Kidney Functions & Urine Formation Made Easy
byBALAJI SOMA
 
PEDIATRIC CATARACT & IT'S MANAGEMENT BY SAMIKSHA RAI
bySamikshaRai22
 
Frameworks for Identifying Systemic Sclerosis and Its Complications: From Pat...
byPVI, PeerView Institute for Medical Education
 
Pathways to Personalized Remission in CLL: Leveraging Targeted Standards & Ne...
byPVI, PeerView Institute for Medical Education
 
How Nepali Politics Collapsed the Health System l A Critical Analysis
byPublic Health Concern Nepal
 
Tyler Hughey Gainesville FL - A Dual-Certified Cardiovascular Sonographer
byTyler Hughey Gainesville FL
 
KNEE JOINT -Prof.Dr.N.Mugunthan, KMMC Medical College & Hospitals.pdf
byKanyakumari Medical Mission Research Center, Muttom
 
Regulatory Guidelines for Biosimilars.pdf
byManoj Konde
 
Cognitive Shadows : Analyzing Modern Traversals of Trauma-Based Mind Control ...
byGAURAV. H .TANDON
 
Systemic Sclerosis (Scleroderma): Clinical Features, Investigations, and Mana...
byAkif Ibn Salam
 
Histology of Musculoskeletal Tissues.pptx
byDaniel Komolafe
 
How to Transform Clinical Practice into Evidence: A Practical Guide to Eviden...
byDaradia: The Pain Clinic
 
Best Ayurvedic Sexologist in Madhepura, Bihar Dr. Sunil Dubey
byDubey Clinic
 
JANUARY 2026 ONCOLOGY CARTOONS BY DR KANHU CHARAN PATRO
byKanhu Charan
 
Special Senses (RIT): Vision, Hearing & Taste Explained with Clinical Correlates
byBALAJI SOMA
 
Fetal Skull detailed study in Obstetrics mainly for medicos
byJoslinPratheejaJ
 
Sweet Dreams - an ILC Partners webinar on sleep
byILC- UK
 
How to Obtain Your Medical Certificate Digitally
bydoccertau
 
Best Selection of Sexologist in Munger, Bihar Male Sexual Problems Dr. Sunil ...
byDubey Clinic
 
Immunologic disorders.pptx pathology for pharmacy
bytadessefiraol9
 
Human Excretory System (RIT): Kidney Functions & Urine Formation Made Easy
byBALAJI SOMA
 

Progressive multifocal leukoencephalopathy (PML)

  • 1.
    Amr Hassan, MD,FEBN Professorof Neurology Cairo University - Egypt Progressive multifocal leukoencephalopathy (PML)
  • 2.
    ▪ John Cunninghamvirus (JCV) is a double-stranded DNA polyomavirus. ▪ Takes its name from the initials of the patient from whom it was first isolated. ▪ PML was initially described in patients with underlying B-cell lymphoproliferative disorders [1] JC virus
  • 3.
  • 4.
  • 5.
    JCPyV and thedevelopment of PML
  • 6.
    JCPyV and thedevelopment of PML
  • 7.
    JCPyV and thedevelopment of PML
  • 15.
    ▪ 50-90% ofadults have been exposed to this virus ▪ 19-27% of these people shedding JCV in their urine.[5,7-10] ▪ Acquisition of this virus is not associated with a clinical syndrome.[9] ▪ Opportunistic infection, caused by the polyoma virus JC virus ▪ Characterized by focal demyelination in the CNS ▪ Worldwide distribution, seroprevalence of 39-69% in adults ▪ Primary infection usually in childhood ▪ No recognized acute JC virus infection ▪ Likely asymptomatic chronic carrier state PML: epidemiology
  • 16.
    In a largereview spanning the 30 years from 1958 to 1984, only 230 cases were identified, with only 69 being confirmed pathologically. PML: epidemiology
  • 17.
  • 19.
    • B-cell malignancies •Other myeloproliferative diseases, • Carcinomas • Congenital immune deficiencies • Organ transplantation • Granulomatous, inflammatory,or other immune- mediated conditions. • 3-7% of persons with AIDS Conditions associated with PML
  • 20.
    – Adenosine deaminasedeficiency – CD40 ligand deficiency – Comimmune deficiency bined – Common variable immune deficiency – DOCK8 (dedicator of cytokinesis 8 protein) deficiency – Gamma heavy chain disease – Hyper-IgM syndrome – Immunodeficiency-centromeric instability-facial dysmorphism syndrome syndrome –Purine nucleoside phosphorylase deficiency – Severe combined immune deficiency – Signal transducer and activator of transcription 1 gain-of-function immune deficiency – Wiskott-Aldrich syndrome – X-linked agammaglobulinaemia – Idiopathic CD4+ lymphopenia* Zerbe CS, Marciano BE, Katial RK, Santos CB, Adamo N, Hsu AP, et al.Progressive Multifocal Leukoencephalopathy in Primary Immune Deficiencies: Stat1 Gain of Function and Review of the Literature. Clin Infect Dis. 2016;62(8):986–94. Hereditary immune deficiencies linked to PML
  • 21.
    – Human immunodefiencyinfection or acquired immune deficiency syndrome – Haematopietic stem cell transplantation – Immunosuppressive therapy in organ transplant recipients – Haematological malignancies (e.g. lymphomas and leukaemias) – Immunosuppression during chemotherapy of solid cancers – Systemic lupus erythematosus – Sarcoidosis – Immunosuppressive or -modulatory therapy in autoimmune diseases (rheumatoid arthritis, psoriatic arthritis, psoriasis, juvenile idiopathic arthritis, inflammatory bowel disease, ankylosing spondylitis, multiple sclerosis) Brew BJ, Davies NW, Cinque P, Clifford DB, Nath A. Progressive multifocal leukoencephalopathy and other forms of JC virus disease. Nat Rev Neurol. 2010;6(12):667–79. Amend KL, Turnbull B, Foskett N, Napalkov P, Kurth T, Seeger J. Incidence of progressive multifocal leukoencephalopathy in patients without HIV. Neurology. 2010;75(15):1326–32. doi Acquired immune deficiencies linked to PML
  • 22.
    Organ Transplant: Heart, lung,kidney 1/1000 HIV AIDS-defining 1/100 without HART 6/10.000 with HAART Bone marrow Transplant 3.5/10.000 per year Hematologic Malignancies 8.3/100.000 per year In lymphoma Immunomodulatory Treatments (e.g.in MS) Rheumatologic Conditions 1/100.000 per year Conditions associated with PML
  • 23.
    – Natalizumab – Efalizumab –Belimumab – Rituximab – Fingolimod – Dimethylfumarate – Alemtuzumab – Tumour necrosis factor-alpha inhibitors (infliximab, adalimumab, etanercept) – Ofatumumab – Mycophenolate mofetil – Betalacept – Brentuximab – Fludarabine – Ruxolitinib – Leflunomide Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med. 2010;61(1):35–47. Brew BJ, Davies NW, Cinque P, Clifford DB, Nath A. Progressive multifocal leukoencephalopathy and other forms of JC virus disease. Nat Rev Neurol. 2010;6(12):667–79. Zaheer F, Berger JR. Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps. Ther Adv Drug Saf. 2012;3(5):227–39. Berger JR. Classifying PML risk with disease modifying therapies. Mult Scler Relat Disord. 2017;12:59–63. Immunomodulatory treatments linked to PML
  • 24.
    – Natalizumab – Efalizumab –Belimumab – Rituximab – Fingolimod – Dimethylfumarate – Alemtuzumab – Tumour necrosis factor-alpha inhibitors (infliximab, adalimumab, etanercept) – Ofatumumab – Mycophenolate mofetil – Betalacept – Brentuximab – Fludarabine – Ruxolitinib – Leflunomide Immunomodulatory treatments linked to PML Major EO. Progressive multifocal leukoencephalopathy in patients on immunomodulatory therapies. Annu Rev Med. 2010;61(1):35–47. Brew BJ, Davies NW, Cinque P, Clifford DB, Nath A. Progressive multifocal leukoencephalopathy and other forms of JC virus disease. Nat Rev Neurol. 2010;6(12):667–79. Zaheer F, Berger JR. Treatment-related progressive multifocal leukoencephalopathy: current understanding and future steps. Ther Adv Drug Saf. 2012;3(5):227–39. Berger JR. Classifying PML risk with disease modifying therapies. Mult Scler Relat Disord. 2017;12:59–63.
  • 25.
    Least concern : Interferonbeta, glatiramer acetate Some concern: Alemtuzumab (Lemtrada) Teriflunamide (Aubagio) Fingolimod (Gilenya) Dimethyl fumarate (Tecfidera) High concern: Natalizumab (Tysabri) Carson et al. 2009; Berger et al. 2013 Concern for PML
  • 26.
    26 • Focal neurologicdeficits, usually with insidious onset, steady progression over several weeks/months • Demyelinating lesions may involve any region of the brain – Common: occipital lobes (hemianopsia), frontal and parietal lobes (aphasia, hemiparesis, hemisensory deficits), cerebellar peduncles and deep white matter (dysmetria, ataxia) – Spinal cord involvement is rare PML: Clinical Manifestations
  • 27.
    27 • Headache andfever not characteristic (except in severe IRIS) • Seizures in 20% • Cognitive dysfunction may occur but diffuse encephalopathy or dementia is rare PML: Clinical Manifestations
  • 28.
    PML: Radiological diagnosis Anearly progressive multifocal leukoencephalopathy (PML) patient within 6 days of PML diagnosis with a large (A) T2-hyperintense and (B) fluid- attenuated inversion recovery–hyperintense lesion in the right frontal lobe. The lesion was (C) T1 hypointense and (D) diffusion-weighted imaging hyperintense, with sharp scalloped borders toward the gray matter and illdefined borders toward the white matter.
  • 29.
  • 30.
    30 PML, CT scanPML, MRI scan PML: Radiological diagnosis CT scan: single or multiple hypodense, nonenhancing white matter lesions
  • 31.
    PML: Radiological diagnosis Progressivemultifocal leukoencephalopathy (PML) radiographically. (a) Typical lesion of PML as a T2 hyperintensity involving large portion of 1 hemisphere. (b) T2 fluid-attenuated inversion recovery image demonstrating hyperintensity in the bilateral cerebellum consistent with PML
  • 32.
    PML: Radiological diagnosis Contrastenhancement in 10-15% but usually sparse, IRIS PMN may have different appearance An early progressive multifocal leukoencephalopathy (PML) patient who developed PML-immune reconstitution inflammatory syndrome (IRIS). At the time of PML diagnosis, this patient had (A) a diffuse T2-hyperintense lesion in the right frontal lobe and (B, arrows) multiple punctate T2 lesions in the vicinity of the main lesion. The lesion was (C) T1 hypointense and (D) DWI hyperintense. (E) The lesion had increased in size by the IRIS phase, which was 37 days after the first scan, and (F) exhibited contrast enhancement on T1-weighted (T1W) imaging. (G) Ten days later, there was a T1-hyperintense rim around the lesion on precontrast T1W imaging, which (H) did not enhance postcontrast, although punctate enhancement was seen in the contralateral hemisphere.
  • 33.
    PML: Radiological diagnosis Diffusion-weightedimaging and MR spectroscopy may give additional diagnositic information FIGURE 3: (A) In this early progressive multifocal leukoencephalopathy (PML) patient, PML was difficult to distinguish from the confluent lesion burden on the fluid-attenuated inversion recovery (FLAIR) image. (B) However, the hyperintensity in diffusion- weighted imaging identified new areas of abnormality. A further magnetic resonance examination 6 days later showed (C) an increase in size of the right frontal lesion on FLAIR with (D) T1 hypointensity.
  • 34.
    PML: Radiological diagnosis FIGURE4: A patient with an early progressive multifocal leukoencephalopathy lesion filling a segment of the precentral gyrus. The lesion was (A) T2 hyperintense, (B) hyperintense on diffusion- weighted imaging, and (C–E) more readily seen on fluid-attenuated inversion recovery (FLAIR). (A, C) Punctate T2-/FLAIR-hyperintense lesions were seen in the vicinity of the main lesion. (D) The lesion increased in size during the IRIS phase (D; 51 days after the first scan) and (E) the post- IRIS phase (85 days after the first scan). No enhancement was noted at any stage.
  • 35.
    PML: Radiological diagnosis FIGURE5: An early progressive multifocal leukoencephalopathy (PML) patient, 9 days prior to PML diagnosis, shows (A) an unusual cluster of punctate T2- hyperintense lesions, many of which (B) were enhanced with contrast on T1-weighted (T1W) imaging and were diffusion- weighted imaging (DWI) hyperintense. (D) The lesions became confluent on a T2- weighted followup scan 30 days later. (E) There was no contrast enhancement on T1W imaging, but (F) the cluster remained hyperintense on DWI.
  • 36.
    From: Natalizumab-Associated ProgressiveMultifocal Leukoencephalopathy in a Patient With Multiple Sclerosis: A Postmortem Study J Neuropathol Exp Neurol. 2013;72(11):1043-1051. doi:10.1097/NEN.0000000000000005 J Neuropathol Exp Neurol | © 2013, by the American Association of Neuropathologists, Inc. PML: Radiological diagnosis
  • 37.
    PML: Radiological diagnosis Magneticresonance imaging evaluation of multiple sclerosis (MS) and progressive multifocal leukoencephalopathy (PML). After receiving 55 infusions of Natalizumab (May 2013). Axial FLAIR (A) and corresponding contrast enhanced T1W images (B) show MS lesions in the periventricular white matter and a new area of hyperintense FLAIR signal (white arrow) and faint enhancement (black arrow) in the left parietal subcortical white matter.
  • 38.
  • 39.
    PML: Radiological diagnosis Figure3: Evolution of progressive multifocal leukoencephalopathy – Immune reconstitution inflammatory syndrome (PML-IRIS). Axial FLAIR and corresponding contrast enhanced T1W images through the parietal lobe. (A) Ten weeks after Natalizumab discontinuation and before steroid treatment (October 21, 2013), there is further extension of the parietal lobe white matter lesion (white arrows) with associated enhancement (black arrowheads). (B) Eleven weeks after Natalizumab discontinuation and after IV steroid therapy (October 29, 2013), there is decreased enhancement without change in FLAIR signal abnormality. (C) 6- month follow up after steroid treatment, there is further improvement with complete
  • 40.
    Elizabeth C. Neil,and Lisa M. DeAngelis Blood Adv 2017;1:2041-2045 © 2017 by The American Society of Hematology PML: Radiological diagnosis
  • 41.
    Features Characteristics Location SubcorticalLocation is the prime site,thereby involving U-fibers cortex and basal ganglia are often involved; often bilatcral Size Usually > 3cm Borders Sharp toward the gray matter, ill defined toward the white matter Mode of extension Lesions increase in size and new lesions appear Mass effect No mass effect in small or large lesions T2W images Always hyperintense T1W images Typically hypointense ; no reversion of signal intenstiy; hyperintensity is suggestive of PML- IRIS FLALR Always hyperintense ; better appreciated than om T2W images DW images Always hyperintense ; in larger lesions there is a hyperintense rim at the lesion’s edge Perilesional Small, punctate T2-hyperintense lesions in the immediate vicinity of the main lesion are often present Enhancement Frequent enhancement, punctate and/or rimlike Atrophy No atrophy in the early phase Ann Neurol.2012 Nov;72(5):779-87. doi: 10.1002/ana.23676. PML: Radiological diagnosis
  • 42.
    • CSF evaluationfor JC virus DNA (BY PCR): helpful positive; 70-90% sensitive in patients who are not on ART(lower in those on ART) • Specificity 92-100% • Sensitivity 72-93% • Serologic testing generally not useful,but newer approaches under investigation PML: diagnosis
  • 43.
    PML: Brain biopsy •Identification of JC virus; • Oligodendrocytes with intranuclear inclusions • Bizarre astrocytes, • Lipid-laden macrophages
  • 44.
  • 45.
    Features indicative of MSPML Onset Acute Sub-acute Evolution • Over hours to days • Normally stabilise • Resolve spontaneously even without therapy • Over weeks • progressive Clinical Presentation • Diplopia • Paraesthesia • Paraparesis • Optic neuritis • myelopathy • Aphasia • Behavioural or cognitive changes and neuropsychological alteration • Retrochiasmal visual deficits • Hemiparesis • Seizures • Ataxia (for GCN) PML Vs An attack
  • 46.
    Fernández et alNeurologia 2012;27:432-41 PML Vs An attack
  • 47.
    Pei-Ran Ho etal., Risk of natalizumab-associated progressive multifocal eukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies.Lancet,2017.S1474-4422(17)30335-6 PML and Natalizumab
  • 48.
    Global Natalizumab PMLRisk Estimates by Treatment Epoch :March 2017
  • 49.
    As of November30, 2017, the global overall incidence of PML in natalizumab-treated patients is: 4.19 per 1000 patients (95% CI 3.89 to 4.49 per 1000 patients). As of December 7, 2017 there have been 756 confirmed PML cases (753 MS, 3 CD), (205 US, 480 EEA, 71 ROW) 76.5% of patients were alive with varying levels of disability* As of December 7, 2017, the duration of natalizumab dosing prior to PML diagnosis ranged from 8 to 136 doses Biogen, data on file.2017 PML and Natalizumab
  • 50.
    PML and MStherapeutics
  • 51.
  • 52.
    PML Cases inPatients Switching From Natalizumab to Fingolimod • Cases reported at ECTRIMS 2014 • Background: Now >135,800 patient-years of experience with fingolimod accumulated; about 15–20% of patients were pre-exposed to natalizumab1 • Objective: To investigate characteristics of the PML cases under fingolimod (post natalizumab)1 • Data from Novartis pharmacovigilance database1 • 11 reports of PML to date; most had fairly long exposure to natalizumab (2.5–6.0 years, mean 4 years, median 5 years)1,2 • 10/11 cases had PML before fingolimod start or PML occurred within 6 months after switch to fingolimod (washout (n=4) 1–5 months, information around JCV status not always known) • 1 additional case; no previous exposure to natalizumab was reported as PML after 7 months of fingolimod treatment; clinical features and MRI evolution consistent with neuromyelitis optica. Diagnosis made based on the results of CSF showing low copy number of JCV1 • The presenter argued for vigilance for PML following natalizumab discontinuation1 1. Putzki N et al. ECTRIMS 2014. FC3.1; 2. Medscape Pharmacists. September 25, 2014. 52
  • 53.
  • 54.
  • 55.
    PML cases withGilenya in patient not pre-treated with Tysabri • 1st case reported in Feb 2015 1,2 • 49 year old male diagnosed with RRMS in 2009. Received prior treatment with Rebif which was discontinued without initiating any other treatment, switched to Gilenya in October 2010. Diagnosed with PML in January 2015 • No co-existing conditions reported, no concurrent treatment along with Gilenya, never received Tysabi • 2nd case reported in July 20153,4 • 54 year old female, developed PML after taking fingolimod for ~ 2.5 years. The patient had a 13-14 year history of MS and was previously treated with Betaferon for ~ 11 years. She also received mesalazine for ulcerative colitis for the last 4 years • FDA issued a warning regarding the 2 PML cases on Gilenya3 • 3rd case reported on August 17, 20154 • Patient had a history of colorectal cancer treated with chemotherapy and radiation treatment, as well as Crohn’s disease. The role of various risk factors are currently evaluated 55 1. Novartis Press Release on Feb 16, 2015, available on http://www.novartis.com/newsroom/product-related-info-center/gilenya-safety-update.shtml 2. https://beta.mssociety.ca/research-news/article/case-of-pml-reported-in-patient-treated-with-gilenya (accessed Aug 24, 2015). 3. www.fda.gov/Drugs/DrugSafety/ucm456919.htm (accessed Aug 24, 2015) 4. www.medscape.com/viewarticle/849015.
  • 56.
  • 57.
    5 cases wereassociated with DMF use for multiple sclerosis 14 cases for psoriasis. PML and DMF
  • 58.
    PML cases withdimethyl fumarate 1. Rosenkranz et al New Engl. J Med 2015; 372: 1476-1478. 2.http://www.bfarm.de/SharedDocs/Risikoinformationen/Pharmakovigilanz/DE/RI/2015/RI-dimethylfumarat.html Accessed July 21, 2015. 3. http://www.medpagetoday.com/Neurology/MultipleSclerosis/52622?isalert=1&uun=g274661d4296R5269425u&xid=NL_breakingnews_2015-07-16, accessed July 21, 2015 4. Nieuwkamp, e al New Engl. J Med 2015; 372: 1474-1476, 5. Philipp et al 2013 et al, Eur. J Dermatol 2013; 23(3): 339-43 6. Spencer et al, Neurol Neuroimmunol Neuroinflamm 2015;2:e76 • Case 11 : Female, 4.5 years on DMF (participated in the DEFINE trial) • 3.5 years having severe lymphopenia (start 12 month after tx initiation, lymphocyte count, 290 to 580 cells per mm3). Died from complications of pneumonia. • On April 7, 2015, the German authorities mentioned 2 PML cases with Tecfidera (+ 9 with Fumaderm) but no details provided2 • On July 17, 2015, also Biogen confirmed a 2nd PML case with Tecfidera, (likewise no details provided)3 • Role of lymphopenia • About 2% of patients treated with DMF develop lymphopenia < 500 cells per mm3)1 • Monitoring of lymphocyte recommended to prevent severe opportunistic infections4* • In April 2015, Nieuwkamp et al published a PML case with (compounded) DMF for the tx of psoriasis. This patients had no major lymphopenia (nadir 792 cells per mm3) and no other immunosuppressive therapies4 *Researchers increasingly recommend to determine besides the commonly-used differential blood counts also lymphocyte subsets (mainly CD4+ and CD8+ Tcells)5,6Depletion of CD8+ T cells seems to be more pronounced than that of CD4+T cells.6 58
  • 59.
    The PML casewith dimethyl fumarate led to label change in the US 59 Description of the fatal PML case with Tecfidera and initial signs/symptoms of PML Recommendation to obtain complete blood count (CBC) at baseline, after month 6 and in due course every 6-12 months. Interrupt treatment if lymphocyte counts are < 0.5 x 109/L persisting for more than 6 months Note: According to the European label, CBC should be obtained at baseline, after 6 months and thereafter every 6-12 months. No mention of PML in the label Tecfidera US prescribing information, European Tecfidera prescribing information
  • 60.
  • 61.
    • A singlefatal case • Reported in a patient who switched from natalizumab to alemtuzumab. • however, retrospective analysis of the MRI data showed that the onset of PML predated alemtuzumab treatment and, therefore, was attributed to natalizumab treatment Thomas Berger et al., Alemtuzumab Use in Clinical Practice: Recommendations from European Multiple Sclerosis Experts.CNS Drugs. 2017; 31(1): 33–50. PML and Alemtuzumab
  • 62.
  • 64.
    • No specifictreatment • Restoring the immune system: • Antiretrovirals in HIV • Plasma exchange to remove natalizumab • No proven benefit: Ara C, IFN gamma, IL-2, cidofovir, mefloquine, mirtazapine • Case report: 2 patients with CD4 lymphopenia IL-7 and vaccination with JCV VP1 protein Sospedra et al. 2014 Treatment of PML
  • 65.
    • Plasma exchangex3 (over 5-8 days) • Accelerates clearance of free natalizumab • (but still alpha-4 integrin receptor binding) • Side effects: clearance of other medications, hypotension, pulmonary edema (volume shift) Khatri et al. 2009 Treatment of PML
  • 66.
    ▪ Younger ageat PML diagnosis ▪ Lower pre-PML EDSS ▪ Lower JC viral load at diagnosis ▪ More localised brain involvement by MRI at the time of diagnosis ▪ Asymptomatic at diagnosis Factors that appear to be associated with improved survival Factors that do not appear to affect survival ▪ Gender ▪ Prior immunosuppressant therapy ▪ MS duration ▪ Natalizumab exposure at PML diagnosis ▪ Gd enhancement on MRI at diagnosis Survival in PML
  • 67.
    • Clinical worseningdue to improvement of immune function rapid worsening. • Neurological symptoms, fever, seizure. • In most patients with natalizumab (up to 90%). • 3-6 weeks after antiretrovirals or plasma exchange. Immune Reconstitution Syndrome (IRIS)
  • 68.
    Enlarged lesions Contrast enhancement Masseffect Immune Reconstitution Syndrome (IRIS)
  • 69.
    Copyright © 2007American Medical Association. All rights reserved. From: Potential Risk of Progressive Multifocal Leukoencephalopathy With Natalizumab TherapyPossible Interventions Arch Neurol. 2007;64(2):169-176. doi:10.1001/archneur.64.2.169
  • 70.